Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
TEVA(NYSE:TEVA) TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California.
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
TEVA(NYSE:TEVA) TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in September as follows:
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
TEVATeva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Goldman Sachs Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $24
TEVAHow Do Investors Really Feel About Teva Pharmaceutical Indus?
TEVAReported Friday, Teva Showcases Real-World UZEDY Data Demonstrating Lower Relapse Rates, Better Adherence, And Reduced Healthcare Use Compared To Oral Antipsychotics
TEVATeva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
TEVATeva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.
Teva Provides Updates Ahead Of Its Innovation and Strategy Day; Say sInnovative Medicines Franchise On Track To Exceed $5B By 2030, Reaffirms 2027 Financial Targets
TEVAWhere Teva Pharmaceutical Indus Stands With Analysts
TEVATruist Securities Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $25
TEVATeva Pharmaceutical Industries Announces That FDA Granted Fast Track Designation For Investigational TEV-53408, An Anti-IL-15 Antibody, For The Treatment Of People With Celiac Disease On A Gluten-Free Diet; TEV-53408 Is Currently Being Evaluated In A Phas
TEVATeva And Biolojic Design Initiate IND-Enabling Studies Of BD9
TEVATeva Pharma Upsizes Debt Tender Offer To $2.25B, Expands Pool 2 & Pool 3 Caps To $350M Each
TEVATeva Pharmaceutical Industries Announces It Upsized Its Offering From $2B And Priced ~$2.3B Of Its Senior Notes
TEVATeva Launches $2 Billion Bond Buyback to Cut Debt Across Multiple Note Series
TEVATeva Pharmaceuticals Announced That Moody's Investor Services Has Raised The Company's Corporate Credit Rating To Ba1, Outlook Stable From Ba2, Outlook Positive
TEVAJP Morgan Upgrades Teva Pharmaceutical Indus to Overweight, Raises Price Target to $23
TEVAB of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $22
TEVATeva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum
TEVATeva beat Q1 EPS estimates and raised 2025 profit guidance as Austedo sales soared and margins improved, despite missing revenue expectations.
Teva Pharmaceutical Indus Raises FY2025 Adj EPS Guidance From $2.35-$2.65 To $2.45-$2.65 vs $2.55 Est; Narrows FY2025 Sales Guidance From $16.80B-$17.40B To $16.80B-$17.20B vs $17.24B Est
TEVATeva Pharmaceutical Indus Q1 Adj. EPS $0.52 Beats $0.48 Estimate, Sales $3.89B Miss $4.00B Estimate
TEVAWhat Does the Market Think About Teva Pharmaceutical Indus?
TEVATeva And Samsung Bioepis Announce Biosimilar EPYSQLI Injection Now Available In The United States
TEVATeva Announces FDA Filing Acceptance For AJOVY In Pediatric Episodic Migraine Prevention
TEVATeva Highlights Phase 3 SOLARIS Trial Survey Results
TEVATeva Pharmaceutical Sees Q1 EPS $0.52 Vs $0.51 Est.; Revenue $3.994B Vs $4.00B Est.
TEVATeva Pharmaceutical Sees FY25 EPS $2.35-$2.65 Vs $2.58 Est.; Revenue $16.8B-$17.4B Vs $17.10B Est.; Sees First Half Of 2025 Revenues Are Expected To Be Slightly Lower Than Second Half Of 2025 Revenues, With Q1 Revenues Expected To Be Lower Than Q2 Revenue
TEVAForecasting The Future: 6 Analyst Projections For Teva Pharmaceutical Indus
TEVAB of A Securities Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $20
TEVATeva and Medincell Announces FDA Acceptance Of Supplemental New Drug Application for UZEDY(R) Extended-Release Injectable Suspension As A Treatment For Patients With Bipolar I Disorder
TEVATeva Partners With Formycon And Klinge To Commercialize Biosimilar To Eylea In Europe And Israel
TEVAFDA Says Teva Pharmaceuticals USA's Ethinyl Estradiol; Norethindrone Tablet, Chewable Has Been Discontinued
TEVASamsung Bioepis And Teva Enter Partnership For Commercialization Of EPYSQLI In US; Samsung Bioepis Will Be Responsible For Development, Regulatory Registration, Manufacture And Supply Of The Product, While Teva Will Be Responsible For Commercialization
TEVATeva Pharmaceutical CEO Francis Says Expects Generics Prices To Be Pushed Down In 2025
TEVATeva shares are trading higher after the company reported better-than-expected Q3 earnings and raised its guidance.
TEVATeva Forecasts 2024 Revenues Of $16.1B-$16.5B Versus Prior Guidance Of $16.0B-$16.4B And Consensus Of $16.256B
TEVATeva Forecasts 2024 Adjusted EPS Of $2.40-$2.50 Versus Prior Guidance Of $2.30-$2.50 And Consensus Of $2.45
TEVATeva Pharmaceutical Indus Q3 2024 Adj EPS $0.69 Beats $0.66 Estimate, Sales $4.33B Beat $4.12B Estimate
TEVATeva Presents New Tardive Dyskinesia Data At Psych Congress 2024 From The IMPACT-TD Registry, Revealing Differences In Patient Experience Based On Underlying Psychiatric Condition; Registry Revealed Fewer Patients With Psychotic Disorders (36%) Received T
TEVATeva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements In Social Functioning And Quality Of Life In Adults Receiving TEV-'749, A Subcutaneous Long-Acting Injectable As Well As Results Of R
TEVATeva Pharmaceutical Indus's Options Frenzy: What You Need to Know
TEVATeva's Migraine Treatment Effective In Patients With Co-Morbid Depression
TEVAPiper Sandler Downgrades Teva Pharmaceutical Indus to Underweight, Lowers Price Target to $7
TEVATeva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise
TEVARecap: Teva Pharmaceutical Q1 Earnings
TEVATeva Pharmaceutical Indus (NYSE:TEVA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
UPDATE: Teva Cuts FY22 Sales Guidance From $15.6B-$16.2B To $15.4B-$16B vs $15.97B Estimate, Reaffirms Adj. EPS Guidance $2.40-$2.60 vs $2.51 Est.
TEVATeva Pharmaceutical Indus Q1 Adj. EPS $0.55, Inline, Sales $3.66B Miss $3.75B Estimate
TEVATeva Announces Settlement With Lupin Resolving AUSTEDO Patent Dispute
TEVA